Please login to the form below

Not currently logged in


This page shows the latest Exjade news and features for those working in and with pharma, biotech and healthcare.

Novartis kicks back against US corruption charges

Novartis kicks back against US corruption charges

Last November, the company settled civil claims related to allegations of kickbacks involving specialty pharmacy prescribing of Myfortic and thalassaemia treatment Exjade (deferasirox), without admitting any liability.

Latest news

  • Biogen Idec taps Sangamo for blood disorder drugs Biogen Idec taps Sangamo for blood disorder drugs

    Meanwhile, supportive therapies are also available, notably Novartis' Exjade (deferasirox) which was approved in the EU last year to manage iron overload in thalassaemia.

  • Novartis' Exjade gets EU approval for thalassaemia Novartis' Exjade gets EU approval for thalassaemia

    For the first time, Exjade will be available to thalassemia patients who are not regularly transfused but still suffer from the life-altering effects of excess iron," he added. ... Approval in thalassaemia adds to the peak sales potential for Exjade and

  • Novartis' net income up 15 per cent for Q2

    Successful launches included Exjade (deferasirox), which made $192m after receiving regulatory approvals in the US and Europe for the treatment of chronic iron overload, and Certican/Zortress (everolimus) which made $26m

  • New accounts: January

    Intensive care medicine. Reynolds-MacKenzie. Novartis. Exjade. Sickle cell disease. Avenue. Novartis.

  • Bursting the banks

    After a mean of four months, 11 patients discontinued deferoxamine. Deferasirox (Exjade). ... Deferasirox (Exjade, ICL670) has been developed by Novartis, the company that also markets deferoxamine.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...